First-in-Class Antibody
Developing Novel Antibody Biologics to Address Unmet Medical Needs
Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that that contributes to unmet medical needs.
PBP1510
PBP1710
IDC001
IDC005
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
IDC007
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
IDC008
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
Our groundbreaking accomplishments
First-in-Class
mAbs
Monoclonal Antibodies
Category
Monoclonal
Antibody
Pipeline
PBP1510
(Ulenistamab)
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Phase 1/2a Clinical Trial in Europe and U.S. 50%
Pipeline : PBP1510 (Ulenistamab)
Category : Monoclonal Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Phase 1/2a Clinical Trial in Europe and U.S. 50%
Category
Monoclonal
Antibody
Pipeline
PBP1710
(Anti-CTHRC1)
Indication
Solid Tumors
Development Stage
- Prearing For preclinical trial 25%
Pipeline : PBP1710 (Anti-CTHRC1)
Category : Monoclonal Antibody
Indication : Solid Tumors
Development Stage
- Prearing For preclinical trial 25%
bsAbs
Bispecific Antibodies
Category
Bispecific
Antibody
Pipeline
IDC001
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Cloning 20%
Pipeline : IDC001
Category : Bispecific Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Cloning 20%
Category
Bispecific
Antibody
Pipeline
IDC002
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Discovery 10%
Pipeline : IDC002
Category : Bispecific Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Discovery 10%
Category
Bispecific
Antibody
Pipeline
IDC003
Indication
Solid Tumors
Development Stage
- Discovery 10%
Pipeline : IDC003
Category : Bispecific Antibody
Indication : Solid Tumors
Development Stage
- Discovery 10%
Category
Bispecific
Antibody
Pipeline
IDC004
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Discovery 10%
Pipeline : IDC004
Category : Bispecific Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Discovery 10%
Category
Bispecific
Antibody
Pipeline
IDC005
Indication
Solid Tumors
Development Stage
- Discovery candidate 15%
Detailed Information
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
Pipeline : IDC005
Category : Bispecific Antibody
Indication : Solid Tumors
Development Stage
- Discovery candidate 15%
Detailed Information
: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.
Category
Bispecific
Antibody
Pipeline
IDC007
Indication
Critical immune disorders
Development Stage
- Discovery candidate 15%
Detailed Information
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
Pipeline : IDC007
Category : Bispecific Antibody
Indication : Critical immune disorders
Development Stage
- Discovery candidate 15%
Detailed Information
: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.
Category
Bispecific
Antibody
Pipeline
IDC008
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Discovery candidate 15%
Detailed Information
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
Pipeline : IDC008
Category : Bispecific Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Discovery candidate 15%
Detailed Information
: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.
Category
Bispecific
Antibody
Pipeline
IDC009
Indication
Pancreatic cancer,
Ovarian cancer
Development Stage
- Discovery 10%
Pipeline : IDC009
Category : Bispecific Antibody
Indication :
Pancreatic cancer, Ovarian cancer
Development Stage
- Discovery 10%
Category
Bispecific
Antibody
Pipeline
IDC010
Indication
Immune diseases
Development Stage
- Discovery candidate 15%
Pipeline : IDC010
Category : Bispecific Antibody
Indication :
Immune diseases
Development Stage
- Discovery candidate 15%
Fusion Abs
Fusion Antibodies
Category
Fusion
Antibody
Pipeline
IDC331
Indication
Solid Tumors
Development Stage
- Lead optimization 5%
Pipeline : IDC331
Category : Fusion Antibody
Indication :
Solid Tumors
Development Stage
- Lead optimization 5%
Category
Fusion
Antibody
Pipeline
IDC332
Indication
Solid Tumors
Development Stage
- Lead optimization 5%
Pipeline : IDC332
Category : Fusion Antibody
Indication :
Solid Tumors
Development Stage
- Lead optimization 5%
Expanded Access Policy
At Prestige Biopharma, we are committed to developing safe and effective drugs to improve the health and well-being of patients. We recognize that some patients may have serious or life-threatening conditions and are not able to participate in our clinical trials. For these patients, Expanded Access to investigational drugs may be an option.
Currently, our investigational medicines are in early phase development, and we are not yet providing Expanded Access. We believe that participating in our clinical trials is the best way for patients to potentially access our investigational medicines prior to regulatory approval. We consider this approach to be the best opportunity to bring safe and effective treatments to patients. We encourage any person interested in gaining access to our investigational medicines to consult their physician regarding the possibility of participating in one of our clinical trials. Please review the information about Prestige Biopharma’s ongoing clinical trials found on this website as well as at https://clinicaltrials.gov/.
We wish to assure patients that we are constantly evaluating our policies and procedures. As such, Expanded Access may be reassessed in the future as our investigational medicines advance further in clinical trials and more data to support the safety and effectiveness becomes available.
If you have any questions about our Expanded Access policy or our clinical trials, please contact us at info@prestigebio.com.
